Activity Overview

This educational activity is an archive of the live conference held on January 24, 2026.

Target Audience

This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in lung cancer. Other health care professionals interested in the treatment of lung cancer are also invited to participate.

Learning Objectives

• Integrate emerging clinical trial evidence regarding the management of patients with lung cancer into personalized treatment plans
• Apply best practices for identifying and mitigating treatment-related adverse effects associated with novel therapies for lung cancer

Module 3: Immunotherapy and ADCs in NSCLC; Small Cell Lung Cancer; and Joint Session on AEs

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.25 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Inc; Daiichi Sankyo, Inc; and Merck Sharp & Dohme, LLC.

Module 3: Immunotherapy and ADCs in NSCLC; Small Cell Lung Cancer; and Joint Session on AEs

GET STARTED WITH THIS PROGRAM:

Related Content